The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension

European Journal of Cardio-thoracic Surgery

Volumn 30, Issue 3, 2006, Pages 499-507

  Gurbanov, Emin ^a   Shiliang, Xiao ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Muscle; Pulmonary hypertension; Remodeling; Smooth

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; APOPTOSIS SIGNAL REGULATING KINASE 1; B 9972; BRADYKININ B2 RECEPTOR AGONIST; BRADYKININ RECEPTOR AGONIST; COMPACTIN; DICHLOROACETIC ACID; ELASTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN INHIBITOR; RHO KINASE; RHO KINASE INHIBITOR; SIMVASTATIN; SURVIVIN; UNCLASSIFIED DRUG; VASODILATOR AGENT;

APOPTOSIS; BLOOD VESSEL WALL; HUMAN; LUNG ALVEOLUS CELL; LUNG ARTERY; LUNG EMBOLISM; LUNG PRESSURE; LUNG VASOCONSTRICTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

APOPTOSIS; DICHLOROACETATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOVASTATIN; MAP KINASE KINASE KINASE 5; MICROTUBULE-ASSOCIATED PROTEINS; MUSCLE, SMOOTH, VASCULAR; NEOPLASM PROTEINS; PANCREATIC ELASTASE; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; PULMONARY CIRCULATION; RECEPTOR, BRADYKININ B2; SIMVASTATIN; THROMBOSIS; VASOCONSTRICTION;

EID: 33746898591     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2006.05.026     Document Type: Review

References (96)

1. Thomson J.R., Machado R.D., Pauciulo M.W., Morgan N.V., Humbert M., Elliott G.C., Ward K., Yacoub M., Mikhail G., Rogers P., Newman J., Wheeler L., and Higenbottam T. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J Med Genet 37 (2000) 741-745
2. Bailey C.L., Channick R.N., and Rubin L.J. A new era in the treatment of primary pulmonary hypertension. Heart 85 3 (2001) 251-252
3. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., and Kernis J.T. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
4. Rubin L.J. Primary pulmonary hypertension. Chest 104 (1993) 236-250
5. Intengan H.D., and Schiffrin E.L. Roles of apoptosis, inflammation, and fibrosis. Hypertension 38 (2001) 581
6. Mulvany M.J., Baumbach G.L., Aalkjaer C., Heagerty A.M., Korsgaard N., Schiffrin E.L., and Heistad D.D. Vascular remodeling. Hypertension (1996) 505-506
7. Archer S., and Rich S. Primary pulmonary hypertension: a vascular biology and translational research 'work in progress'. Circulation 102 (2000) 2781-2791
8. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 114 (1998) 213S-224S
9. Stenmark K.R., and Mecham R.P. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 59 (1997) 89-144
10. Zhu L., Wigle D., Hinek A., Kobayashi J., Ye C., Zuker M., Dodo H., Keeley F.W., and Rabinovitch M. The endogenous vascular elastase that governs development and progression of monocrotaline-induced pulmonary hypertension in rats is a novel enzyme related to the serine proteinase adipsin. J Clin Invest 94 (1994) 1163-1171
11. Thompson K., Kobayashi J., Childs T., Wigle D., and Rabinovitch M. Endothelial and serum factors which include apolipoprotein A1 tether elastin to smooth muscle cells inducing serine elastase activity via tyrosine kinase-mediated transcription and translation. J Cell Physiol 174 (1998) 78-89
12. Todorovich-Hunter L., Johnson D.J., Ranger P., Keeley F.W., and Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline: a biochemical and ultrastructural study. Lab Invest 58 (1988) 184-195
13. Prosser I., Stenmark K., Suthar M., Crouch E., Mecham R., and Parks W. Regional heterogeneity of elastin and collagen gene expression in intralobar arteries in response to hypoxic pulmonary hypertension as demonstrated by in situ hybridization. Am J Pathol 135 (1989) 1073-1088
14. Botney M.D., Kaiser L.R., Cooper J.D., Mecham R.P., Parghi D., Roby J., and Parks W.C. Extracellular matrix gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol 140 (1992) 357-364
15. Jones P.L., Cowan K., and Rabinovitch M. Tenascin-C, proliferation and subendothelial accumulation of fibronectin in progressive pulmonary vascular disease. Am J Pathol 150 (1997) 1349-1360
16. Jones P.L., and Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79 (1996) 1131-1142
17. Smith P., and Heath D. Ultrastructure of hypoxia hypertensive pulmonary vascular disease. J Pathol 121 (1976) 93-101
18. Tucker A., McMurtry I.I., Reeves J.T., Alexander A.F., Will D.H.H., and Grover R.F. Lung vascular smooth muscle as a determinate of pulmonary hypertension at high altitude. Am J Physiol 228 (1975) 762-767
19. Grover R.F., Vogel J.K., Averill K.H., and Blount S.G. Pulmonary hypertension: individual and species variability relative to vascular reactivity. Am Heart J 66 (1963) 1-3
20. Mulvany M.J. Small artery remodeling and significance in the development of hypertension. News Physiol Sci (2002) 105-109
21. Gibbons G.H., and Dzau V.J. The emerging concept of vascular remodeling. N Engl J Med 330 (1994) 1431-1438
22. Tuttle J.L., Nachreiner R.D., Bhuller A.S., Condict K.W., Connors B.A., Herring B.P., Dalsing M.C., and Unthank J.L. Shear level influences resistance artery remodeling: wall dimensions, cell density, and eNOS expression. Am J Physiol Heart Circ Physiol 281 (2001) H1380-H1389
23. Rizzoni D., Porteri E., Boari G.E.M., De Ciuceis C., Sleiman I., Lorenza Muiesan M., Castellano M., Miclini M., and Agabiti-Rosei E. Prognostic significance of small-artery structure in hypertension. Circulation 108 (2003) 2230
24. Pries A.R., Secomb T.W., and Gaehtgens P. Structural autoregulation of terminal vascular beds. Vascular adaptation and development of hypertension. Hypertension 33 (1999) 153-161
25. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Am Thorac Soc 2 (2005) 20-22
26. Lerman A., Cannan C.R., Higano S.H., Nishimura R.A., and Holmes Jr. D.R. Coronary vascular remodeling in association with endothelial dysfunction. Am J Cardiol 81 (1998) 1105-1109
27. Welsh C.H., Hassell K.L., Badesch D.B., Kressin D.C., and Marlar R.A. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110 (1996) 710-717
28. Weir E.K., and Archer S.L. The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J 9 (1995) 183-189
29. Haunstetter A., and Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 82 (1998) 1111-1129
30. Riley D.J., Thakker-Varia S., Wilson F.J., Poiani G.J., and Tozzi C.A. Role of proteolysis and apoptosis in regression of pulmonary vascular remodeling. Physiol Res 49 (2000) 577-585
31. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
32. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
33. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
34. Zimmermann K.C., Bonzon C., and Green D.R. The machinery of programmed cell death. Pharmacol Ther 92 (2001) 57-70
35. Okada Y., Maeno E., Shimizu T., Dezaki K., Wang J., and Morishima S. Receptor-mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD). J Physiol 532 (2001) 3-16
36. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 87 (2000) 179-183
37. Pollman M.J., Yamada T., Horiuchi M., and Gibbons G.H. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res 79 (1996) 748-756
38. Yamada T., Horiuchi M., and Dzau V.J. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93 (1996) 156-160
39. Cattaruzza M., Dimigen C., Ehrenreich H., and Hecker M. Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J 14 (2000) 991-998
40. Li P.F., Maasch C., Haller H., Dietz R., and von Harsdorf R. Requirement for protein kinase C in reactive oxygen species-included apoptosis of vascular smooth muscle cells. Circulation 100 (1999) 967-973
41. Tea B.S., Der Sarkissian S., Touyz R.M., Hamet P., and deBlois D. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension 35 (2000) 1069-1073
42. 2 angiotensin receptors in apoptosis of rat blood vessels. Hypertension 34 (1999) 617-624
43. Earnshaw W.C., Martins L.M., and Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68 (1999) 383-424
44. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome C from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
45. Duchen M.R. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. J Physiol 516 (1999) 1-17
46. Bernardi P. Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol Rev 79 (1999) 1127-1155
47. Yu S.P., Yeh C.-H., Sensi S.L., Gwag B.J., Canzoniero L.M.T., Farhangrazi Z.S., Ying H.S., Tian M., Dugan L.L., and Choi D.W. Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 278 (1997) 114-117
48. + efflux in the activation of apoptosis. J Biol Chem. 272 (1997) 32436-32442
49. + channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol 280 (2001) C970-C979
50. Vu C.C.Q., Bortner C.D., and Cidlowski J.A. Differential involvement of initiator caspases in apoptotic volume decrease and potassium efflux during Fas- and UV-induced cell death. J Biol Chem 276 (2001) 37602-37611
51. Nietsch H.H., Roe M.W., Fiekers J.F., Moore A.L., and Lidofsky S.D. Activation of potassium and chloride channels by tumor necrosis factor α. Role in liver cell death. J Biol Chem 275 (2000) 20556-20561
52. Trimarchi J.R., Liu L., Smith P.J.S., and Keefe D.L. Apoptosis recruits two-pore domain potassium channels used for homeostatic volume regulation. Am J Physiol Cell Physiol 282 (2002) C588-C594
53. Hockenbery D.M., Oltvai Z.N., Yin X.M., Milliman C.L., and Korsmeyer S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75 (1993) 241-251
54. Smeyne R.J., Vendrell M., Hayward M., Baker S.J., Miao G.G., Schilling K., Robertson L.M., Curran T., and Morgan J.I. Continuous c-fos expression precedes programmed cell death in vivo. Nature 363 (1993) 166-169
55. Lane D.P. p53, guardian of the genome. Nature 358 (1993) 15-16
56. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., and Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362 (1993) 849-852
57. The International PPH Consortium, Lane K.B., Machado V.C., Pauciulo M.W., Thomson J.R., Phillips III J.A., Loyd J.E., Nichols W.C., and Trembath R.C. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26 (2000) 81-84
58. Deng Z., Morse J.H., Slager S.L., Cuervo N., Moore K.J., Venetos G., Kalachikov S., Cayanis E., Ficsher S.G., Barst R.J., Hodge S.E., and Knowles J.A. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
59. Jones P.L., Crack J., and Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the avb3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 139 (1997) 279-293
60. Patel M.I., Melrose J., Ghosh P., and Appleberg M. Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J Vasc Surg 24 (1996) 82-92
61. Uhal B.D. Apoptosis in lung fibrosis and repair. Chest 122 Suppl 6 (2002) 293S-298S
62. Voelkel N.F., and Tuder R.M. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Pul Pharmacol Ther 10 (1997) 231-241
63. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., and Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 6 (2000) 698-702
64. Cowan K.N., Jones P.L., and Rabinovitch M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 84 (1999) 1223-1233
65. Zhang S., Fantozzi I., Tigno D.D., Yi E.S., Platoshyn O., Thistlethwaite P.A., Kriett J.M., Yung G., Rubin L.J., and Yuan J.X.-J. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 285 (2003) L740-L754
66. Durmowicz A.G., and Stenmark K.R. Mechanisms of structure remodeling in chronic pulmonary hypertension. Pediatr Rev (online) 20 (1999) e91-e102
67. Bjorkerud S., Bjorkerud B., and Joelsson M. Structural organization of reconstituted human arterial smooth muscle tissue. Arterioscler Thromb 14 (1994) 644-651
68. Cowan K.N., Jones P.L., and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 105 (2000) 21-34
69. Qing F., McCarthy T.J., Markham J., and Schuster D.P. Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans: a positron emission tomography study. Am J Respir Crit Care Med 161 (2000) 2019-2025
70. Rubin L.J. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 166 (2002) 1308-1309
71. Mulvany M.J. Determinants of vascular structure. J Cardiovasc Pharmacol 19 Suppl 5 (1992) S1-S6
72. Mulvany M.J. The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol 19 Suppl 2 (1992) S22-S27
73. Safar M.E., Levy B.I., and London G.M. Arterial structure in hypertension and the effects of angiotensin converting enzyme inhibition. J Hypertens Suppl 10 (1992) S51-S57 Review
74. Dispersyn G., Nuydens R., Connors R., Borgers M., and Geerts H. Bcl-2 protects against FCCP-induced apoptosis and mitochondrial membrane potential depolarization in PC 12 cells. Biochim Biophys Acta 1428 (1999) 357-371
75. Fernández-Salas E., Sagar M., Cheng C., Yuspa S.H., and Weinberg W.C. p53 and tumor necrosis factor α regulate the expression of a mitochondrial chloride channel protein. J Biol Chem 274 (1999) 36488-36497
76. Weir E.K., Rubin L.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Elliott C.G., Fishman A.P., Goldring R.M., and Groves B.M. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 140 (1989) 1623-1630
77. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
78. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
79. Pasque M.K., Trulock E.P., Kaiser L.R., and Cooper J.D. Single-lung transplantation for pulmonary hypertension: three-month hemodynamic follow-up. Circulation 84 (1991) 2275-2279
80. Glanville A.R., Burke C.M., Theodore J., and Robin E.D. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 91 (1987) 675-681
81. Smith P., and Heath D. Ultrastructure of hypoxia hypertensive pulmonary vascular disease. J Pathol 121 (1976) 93-101
82. McMurtry M.S., Archer S.L., Altieri D.C., Bonnet S., Haromy A., Harry G., Bonnet S., Puttagunta L., and Michelakis E.D. Gene therapy targeting survivin selectivity induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115 (2005) 1479-1491 10.1172/JCI23203
83. Blanc-Brude O.P., Yu J., Simosa H., Conte M.S., Sessa W.C., and Altieri D.C. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 8 (2002) 987-994
84. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3 (2003) 46-54
85. Kip 1. J Biol Chem 274 (1999) 21926-21931
86. Indolfi C., Cioppa A., Stabile E., Di Lorenzo E., Esposito G., Pisani A., Leccia A., Cavuto L., Stingtone A.M., Chieffo A., Capozzolo C., and Chiariello M. Effects of hydroxymethylglutaryl coenzyme A reducates inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 35 (2000) 214-221
87. Fouty B.W., and Rodman D.M. Mevastatin Can Cause G1 Arrest and Induce Apoptosis in Pulmonary Artery Smooth Muscle Cells Through a p27Kip1-Independent Pathway. Circ Res 92 5 (2003) 501-509
88. Nishimura T., Vaszar L.T., Faul J.L., Zhao G., Berry G.J., Shi L., Qiu D., Benson G., Pearl R.G., and Kao P.N. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108 (2003) 1640
89. Chang H.Y., Nishitoh H., Yang X., Ichijo H., and Baltimore D. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 281 (1998) 1860-1863
90. Izumi Y., Kim S., Yoshiyama M., Izumiya Y., Yoshida K., Matsuzawa A., Koyama H., Nishizawa Y., Ichijo H., Yoshikawa J., and Iwao H. Activation of apoptosis signal-regulating kinase 1 in injured artery and its critical role in neointimal hyperplasia. Circulation 108 (2003) 2812
91. Matsuda Y., Hoshikawa Y., Ameshima S., Suzuki S., Okada Y., Tabata T., Sugawara T., Matsumura Y., and Kondo T. Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 43 5 (2005) 283-288
92. Taraseviciene-Stewart L., Scerbavicus R., Stewart J.M., Gera L., Demura Y., Cool C., Kasper M., and Voelkel N.F. Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26 8 (2005) 1292-1300
93. Sean McMurtry M., Bonnet S., Wu X., Dyck J.R.B., Haromy A., Hashimoto K., and Michelakis E.D. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circulation 95 (2004) 830
94. Merklinger S.L., Jones P.L., Martinz E.C., and Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112 3 (2005) 423-431
95. Shibata R., Kai H., Seki Y., Kato S., Morimatsu M., Kaibuchi K., and Imaizumi T. Role of rho-associated kinase in neointima formation after vascular injury. Circulation 103 (2001) 284
96. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., Hattori T., Nakashima Y., Kaibuchi K., Sueishi K., and Takeshita A. Long-term treatment with a rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circulation 94 (2004) 385